These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22929717)

  • 1. Role of CaCO3 alone and CaCO3 plus vitamin D3 in terms of calcium phosphorus product in chronic kidney diseases.
    Adhikary L; Acharya S; Acharya L
    J Nepal Health Res Counc; 2011 Apr; 9(1):67-70. PubMed ID: 22929717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
    Okada K; Nagura Y; Takahashi S; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
    Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
    Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral calcium carbonate as phosphate-binder in infants and children with chronic renal failure.
    Alon U; Davidai G; Bentur L; Berant M; Better OS
    Miner Electrolyte Metab; 1986; 12(5-6):320-5. PubMed ID: 3807830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of H2-blockers on serum calcium and phosphorus in hemodialysis patients on calcium carbonate therapy.
    Kushihata S; Yorioka N
    Clin Nephrol; 1998 Sep; 50(3):198-9. PubMed ID: 9776428
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which therapy to prevent post-thyroidectomy hypocalcemia?
    Pisaniello D; Parmeggiani D; Piatto A; Avenia N; d'Ajello M; Monacelli M; Calzolari F; Sanguinetti A; Parmeggiani U; Sperlongano P
    G Chir; 2005 Oct; 26(10):357-61. PubMed ID: 16371185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of calcium carbonate as a phosphate binder in dialysis patients.
    Hercz G; Kraut JA; Andress DA; Howard N; Roberts C; Shinaberger JH; Sherrard DJ; Coburn JW
    Miner Electrolyte Metab; 1986; 12(5-6):314-9. PubMed ID: 3807829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early treatment of secondary hyperparathyroidism in moderate renal insufficiency: low-phosphorus diet versus calcium carbonate].
    Aresté N; Amor J; Cambil T; Salgueira M; Sánchez-Palencia R; Páez C; Gómez O; Palma A
    Nefrologia; 2003; 23 Suppl 2():64-8. PubMed ID: 12778857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study.
    Delmez JA; Kelber J; Norword KY; Giles KS; Slatopolsky E
    Kidney Int; 1996 Jan; 49(1):163-7. PubMed ID: 8770963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
    Coyne DW; Grieff M; Ahya SN; Giles K; Norwood K; Slatopolsky E
    Am J Kidney Dis; 2002 Dec; 40(6):1283-8. PubMed ID: 12460048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of high CaCO3 supplements on serum calcium and phosphorus in patients on regular hemodialysis treatment.
    Gonella M; Calabrese G; Vagelli G; Pratesi G; Lamon S; Talarico S
    Clin Nephrol; 1985 Sep; 24(3):147-50. PubMed ID: 4042444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.